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Impact of thyroid dysfunction on serum cystatin C. tually increased creatinine release by muscle cells seem
Background. Serum cystatin C (CysC) is a novel marker for to be responsible for elevated serum creatinine levels
kidney function that has been claimed to be superior to serum observed in patients with hypothyroidism [1–3]. In con-creatinine. Thyroid dysfunction may alter creatinine, which has
trast, decreased serum creatinine levels may be encoun-been found to be increased in hypothyroidism and decreased
in hyperthyroidism. This study was performed to evaluate whe- tered in patients with hyperthyroidism [3, 4].
ther changes in CysC and creatinine are parallel during the In 1985, serum cystatin C (CysC) was introduced as a
treatment of hypo- and hyperthyroidism, respectively. new marker of kidney function [5]. CysC is a low molecu-Methods. Prospective case series of 22 consecutively referred
lar weight, basic protein that functions as a physiologicpatients with thyroid dysfunction. Creatinine and CysC were
inhibitor of cysteine proteinases [6]. CysC is considereddetermined at the time of diagnosis of hypo- and hyperthyroid-
ism, and when free thyroxine (fT4) returned into the normal to be produced at a constant rate by most nucleated cells
range. Hypothyroid patients were treated with levothyroxine. [7]. The structure of its gene is of the housekeeping typeHyperthyroid patients were treated with antithyroid drugs,
and the production of CysC is not influenced by inflam-surgery, or radioiodine.
matory states [7]. The protein is freely filtered at theResults. Nine patients with hypothyroidism and 13 patients
with hyperthyroidism were included. In patients with hypothy- glomerulus and practically completely reabsorbed and
roidism mean fT4 (SD) was 4.9  2.5 pmol/L (reference, 12 catabolized by tubular cells [8]. Compared to serum cre-
to 22) at diagnosis and increased to 16.6  3.6 pmol/L when
atinine, CysC has a lower interindividual variability and ispatients were treated with levothyroxine. Creatinine decreased
not correlated to lean tissue mass, gender, and age [9, 10].from 86 13 mol/L (reference, 70 to 105) in the hypothyroid
state to 76  16 mol/L when fT4 normalized (P  0.062), CysC has proved to be a reliable marker of glomerular
whereas CysC increased from 0.84  0.17 mg/L (reference, filtration rate (GFR) in healthy adults and children as
0.63 to 1.33) to 1.1  0.28 mg/L (P  0.001). In patients with
well as in patients with renal disorders of rheumatologic,hyperthyroidism, mean fT4 was 54.6 22.7 pmol/L (reference,
nephrologic, hepatic, and neoplastic origin [11–14]. In a12 to 22) at diagnosis and decreased to 15.8  3.6 pmol/L
following treatment with antithyroid drugs, thyroid surgery, or review of 24 studies, CysC was found to be an estimator
radioiodine. Creatinine increased from 67  15 mol/L at of the GRF at least as well as serum creatinine in the
diagnosis of hyperthyroidism to 75  9 mol/L when fT4 nor-
population at large and likely even superior in specificmalized (P  0.004), whereas CysC declined from 1.32  0.17
patient populations [15].mg/L to 0.95  0.19 mg/L (P  0.001).
Conclusion. Thyroid dysfunction has a major impact on To the best of our knowledge, an influence of thyroid
CysC levels. Therefore, thyroid function has to be considered dysfunction on serum CysC levels has not been described
when CysC is used as a marker of kidney function. In contrast
before. The aim of this study was to evaluate whetherto creatinine concentrations, CysC levels are lower in the hypo-
parallel changes in CysC and serum creatinine could bethyroid and higher in the hyperthyroid state as compared with
the euthyroid state. observed in patients with hypothyroidism and hyperthy-
roidism, reflecting presumed effects of thyroid hormones
on kidney function.
Thyroid dysfunction is known to influence serum cre-
atinine levels. Decreased creatinine clearance and even-
METHODS
Key words: serum cystatin C, thyroid dysfunction, creatinine. Patients with newly diagnosed hypo- or hyperthyroid-
ism who had been referred to the Division of Endocrinol-
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Patients with subclinical hypo- or hyperthyroidism and (P 0.062) when fT4 had normalized. In contrast, CysC
patients with altered kidney function at study end (de- increased from 0.84  0.17 mg/L to 1.1  0.28 mg/L
fined as serum creatinine above the normal range) were (P 0.001) in the same period. Changes of serum creati-
excluded from the analysis. Informed consent to deter- nine and CysC of all individual patients are demon-
mine additional laboratory values (serum creatinine and strated in the Figure 1 A and B. Two patients with im-
CysC) was obtained from all patients. CysC, serum creat- paired kidney function due to hypertension at study end
inine, and free thyroxine (fT4) were measured in the hypo- were excluded from the analysis; they showed the same
or hyperthyroid state, respectively, and when fT4 had change of serum creatinine and CysC on a higher level.
returned into the normal range. Thyroid function was The exclusion of these patients had no influence on the
monitored with fT4 because patients with secondary hy- conclusion of our study.
pothyroidism were also included in the study and be-
Hyperthyroidismcause thyroid-stimulating hormone (TSH) often remains
suppressed in previously hyperthyroid patients for a Thirteen patients (nine female and four male) with
longer period of time. Blood samples were taken before primary hyperthyroidism were included. Hyperthyroid-
the intake of the daily medication (i.e., levothyroxine). ism resulted from Graves’ disease in 11 patients, from
Samples were immediately centrifuged and analyzed on toxic multinodular goiter in one patient, and in another
the same day. patient from suppressive therapy with levothyroxine.
fT4 was measured by a electrochemoluminescence im- The median age (range) at diagnosis was 43 (22 to 86)
munoassay (Elecsys, Roche, Rotkreuz, Switzerland) years. One patient was known to have glomerulonephri-
with a reference range from 12 to 22 pmol/L and a coeffi- tis, but her serum creatinine was within the normal range.
cient of variation (CV  standard deviation/arithmetic Mean fT4 at diagnosis of hyperthyroidism was 54.6 
mean) of 14.5% (measured at a value of 5.1 pmol/L). 22.7 pmol/L. TSH levels were undetectable in 12 patients,
CysC was measured by an immunologic turbidimetric one patient had a TSH level of 0.07 mU/L (reference,
assay (Cobas Integra, DAKO Diagnostics, Zug, Switzer- 0.27 to 4.2). Nine patients were treated with antithyroid
land) with a reference range from 0.63 to 1.33 mg/L
drugs, two patients underwent thyroid surgery, and one
and a CV of 3.8% (1.35 mg/L). Serum creatinine was
patient received radioiodine. Doses of levothyroxinemeasured by a kinetic Jaffe´ reaction (Hitachi Modular
were reduced in the patient with suppressive therapy. InSystem, Roche, Rotkreuz, Switzerland) with a reference
all patients, fT4 returned to normal (fT4 15.8  3.6range from 60 to 105 mol/L and a CV of 1.7% (94
pmol/L) within 12 8 weeks; TSH levels remained unde-mol/L).
tectable in eight patients and were below the normalStatistical analyses were performed using SAS Version
range in five patients. Serum creatinine increased from8.2 (SAS institute, Inc., Cary, NC, USA). Mean and
67  15 mol/L at diagnosis of hyperthyroidism to 75 standard deviation were used for descriptive statistics.
9 mol/L (P  0.004) when fT4 had normalized. In con-Values before and after treatment within the two groups
trast, CysC decreased from 1.32  0.17 mg/L to 0.95 were analyzed using paired Student t test. A P value
0.19 mg/L (P  0.001) during the same period. Changes0.05 was considered statistically significant.





Nine patients (eight female and one male) with hypo-
Thyroid dysfunction is associated with changes in se-thyroidism were included; seven with primary hypothy-
rum creatinine. In agreement with previous reports, se-roidism and two with secondary hypothyroidism due to
rum creatinine values in our study were higher in hypo-pituitary disorders. Primary hypothyroidism resulted
thyroidism and lower in hyperthyroidism as comparedfrom chronic autoimmune thyroiditis in five patients and
with the values of the same individual in the euthyroidfrom thyroid surgery or radioiodine (I131) ablation in two
state. By contrast, we observed inverse changes of CysCpatients. Median age (range) at diagnosis was 34 (14 to
levels in patients with thyroid dysfunction. CysC levels52) years. Mean fT4 at diagnosis was 4.9  2.5 pmol/L.
were significantly lower in hypothyroidism and signifi-Mean TSH in patients with primary hypothyroidism was
cantly higher in hyperthyroidism compared to the eu-198  224 mU/L (reference, 0.27 to 4.2). All patients
thyroid state. The inverse changes in CysC and serumwere treated with levothyroxine. Thyroxine substitution
creatinine seen in patients with thyroid hormone defi-increased fT4 levels to 16.6  3.6 pmol/L within 13  5
ciency and excess, respectively, suggest that the effectsweeks. TSH decreased in patients with primary hypothy-
of thyroid hormones on GFR are overridden by theroidism to 2.6  2.5 mU/L. Serum creatinine declined
from 86  13 mol/L at diagnosis to 76  16 mol/L effects of thyroid hormones on CysC. Medications with
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Fig. 1. Serum creatinine and cystatin C (CysC) in patients treated for hypothyroidism (A and B) and hyperthyroidism (C and D). Values are
shown at diagnosis of hypothyroidism and hyperthyroidism, respectively, and when free thyroxine (fT4) returned into the normal range.
a relevant influence on serum creatinine have not been was not assessed systematically in studies investigating
the utility of CysC as a marker of kidney function.prescribed to our patients.
CysC is considered to be produced in all nucleated Due to the major impact of thyroid hormones on CysC
demonstrated in our study, we recommend that alteredcells at a constant rate [7]. The influence of thyroid
hormones on CysC observed in our study may be ex- thyroid function should be considered when CysC is
determined.plained by an altered production rate of CysC in the
context of a changed cell turnover and/or metabolic rate
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likely explanation. Despite a rather small number of pa-
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